JP2017125002A - Bitter taste suppressing method using mannitol powders - Google Patents

Bitter taste suppressing method using mannitol powders Download PDF

Info

Publication number
JP2017125002A
JP2017125002A JP2016077765A JP2016077765A JP2017125002A JP 2017125002 A JP2017125002 A JP 2017125002A JP 2016077765 A JP2016077765 A JP 2016077765A JP 2016077765 A JP2016077765 A JP 2016077765A JP 2017125002 A JP2017125002 A JP 2017125002A
Authority
JP
Japan
Prior art keywords
mannitol
bitter
tablets
tablet
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016077765A
Other languages
Japanese (ja)
Inventor
知香子 早房
Chikako Hayafusa
知香子 早房
悠貴 保田
Yuki Yasuda
悠貴 保田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Shoji Foodtech Co Ltd
Original Assignee
Mitsubishi Shoji Foodtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Shoji Foodtech Co Ltd filed Critical Mitsubishi Shoji Foodtech Co Ltd
Publication of JP2017125002A publication Critical patent/JP2017125002A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide methods of suppressing bitter taste of bitter substances more effectively than conventional methods, for pharmaceuticals or various foods.SOLUTION: An obtained tablet by using, as a tablet raw material, mannitol powders of which 60% or more has a size of 75 μm or less and which has a specific surface area of 0.20 m/g or more to less than 0.64 m/g has a sweet taste starting properties, sweet taste sharpening properties, and sweet taste strength which are improved by the effect of a rapid dissolution rate, and can suppress the bitterness of a bitter substance taken together.SELECTED DRAWING: None

Description

本発明は、特定の比表面積および粒度をもつマンニトール粉末を錠剤用原料として用い、苦味物質の苦味を抑制する方法に関する。   The present invention relates to a method for suppressing bitterness of a bitter substance using mannitol powder having a specific surface area and particle size as a raw material for tablets.

医薬品や食品の中には、苦味を有するものが含まれている。医薬品成分においては、苦味のある物質が特に多く、服用者に不快感を与えるものが多い。そのため、服用者のQOLを向上させる観点から、さまざまな工夫がなされていたが、より効果的に、苦味物質の苦味を抑制するための技術開発が求められていた。また、食品においても、健康に寄与するため、摂食したいものであるにも関わらず、苦味を有しているばかりに、積極的な摂食が好まれないものがあった。それゆえ、医薬品のみではなく、種々の食品を対象とした、苦味抑制技術の開発が望まれていた。   Some drugs and foods have a bitter taste. Among the pharmaceutical ingredients, there are many substances having a bitter taste, and many of them give discomfort to the user. For this reason, various ideas have been made from the viewpoint of improving the QOL of the user, but there has been a demand for technical development for more effectively suppressing the bitterness of bitter substances. In addition, some foods have a bitter taste and do not like active eating because they contribute to health but have a bitter taste. Therefore, development of bitterness suppression technology not only for pharmaceuticals but also for various foods has been desired.

従来、苦味を抑制する方法として、苦味成分と共にエリスリトールを必須成分として配合した即効性医薬製剤が発明されたが(特許文献1)、特許文献1の発明は、エリスリトールの甘みや苦み、清涼感、嗜好性等によってエリスリトールが選択できない場合は適用することができなかった。   Conventionally, as a method for suppressing bitterness, a fast-acting pharmaceutical preparation in which erythritol is blended as an essential component together with a bitter component has been invented (Patent Document 1), but the invention of Patent Document 1 describes the sweetness and bitterness of erythritol, a refreshing feeling, When erythritol could not be selected due to palatability, etc., it could not be applied.

一方、各種食品及び各種医薬品の基剤、あるいは錠剤や散剤の賦形剤などに幅広く使用されているものとして、マンニトールがある。マンニトールは、六炭糖の糖アルコールの一種であり、安定性に優れ、白色の結晶性粉末で臭いはなく、適度な甘みと清涼感を有するため、嗜好性に優れている。また、スクロースやグルコースよりも低カロリーで、医薬品成分等の活性成分との反応性が少ないため、様々な薬物に使用でき、人体に対して安全であるなどの特性を持つ。   On the other hand, mannitol is widely used as a base for various foods and various pharmaceuticals, or an excipient for tablets and powders. Mannitol is a kind of sugar alcohol of hexose sugar, has excellent stability, is white crystalline powder, has no odor, has an appropriate sweetness and a refreshing feeling, and has excellent palatability. In addition, it has lower calories than sucrose and glucose, and has less reactivity with active ingredients such as pharmaceutical ingredients, so that it can be used for various drugs and is safe for the human body.

近年、苦味物質を含有する粒子と甘味物質を含有する粒子の経口固形組成物が開発されており、薬効成分や食品成分の不快な味を抑制する方法が開示されている(特許文献2)。より詳細には、不快味成分を含む粒子のうち、150μm以下の粒子が組成物全体の7%以下となるようにし、さらに甘味物質の平均粒子径を150μm以下とすることで、目的を達成するものである。甘味物質としては、マンニトールが例示されている。しかし、特許文献2の発明は、マンニトール粉末の平均粒子径が150μm以下であっても、苦味抑制効果が十分でない場合があった。   In recent years, oral solid compositions of particles containing a bitter substance and particles containing a sweet substance have been developed, and a method for suppressing the unpleasant taste of medicinal ingredients and food ingredients has been disclosed (Patent Document 2). More specifically, among the particles containing an unpleasant taste component, the particle size of 150 μm or less is 7% or less of the entire composition, and the average particle size of the sweet substance is 150 μm or less to achieve the object. Is. As the sweet substance, mannitol is exemplified. However, in the invention of Patent Document 2, even when the average particle size of the mannitol powder is 150 μm or less, the bitterness suppressing effect may not be sufficient.

特開2001−89396号公報JP 2001-89396 A 特開2005−8640号公報JP 2005-8640 A

本発明は、かかる事情に鑑みて発明されたものであり、従来よりもさらに効果的に、苦味物質の苦味を抑制する方法を提供することを目的とする。   This invention is invented in view of this situation, and it aims at providing the method of suppressing the bitterness of a bitter substance more effectively than before.

上記課題を解決するために鋭意研究したところ、本発明者らは、特定の比表面積および粒度をもつマンニトール粉末を錠剤用原料として用い、苦味物質の苦味を抑制する方法を確立し、本発明を完成するに至った。   As a result of diligent research to solve the above problems, the present inventors established a method for suppressing the bitter taste of bitter substances using mannitol powder having a specific surface area and particle size as a raw material for tablets. It came to be completed.

より詳細には、本発明者らは、75μm以下の粒子が60%以上であり、比表面積が0.20m/g以上0.64m/g未満であるマンニトール粉末を錠剤用原料として用い、速い溶解速度の作用により、甘味の立ち上がり方・甘味のキレ方・甘味強度を向上させ、従来よりもさらに効果的に、苦味を抑制できる方法を確立した。 More particularly, the present inventors is a 75μm or less of the particles more than 60%, a specific surface area using a mannitol powder is less than 0.20 m 2 / g or more 0.64 m 2 / g as tablet material, A method has been established that can improve bitterness more effectively than before by improving the sweetness rising method, sweetness sharpness, and sweetness intensity by the action of a high dissolution rate.

すなわち、本発明は、75μm以下の粒子が60%以上であり、比表面積が0.20m/g以上0.64m/g未満であるマンニトール粉末を錠剤用原料として用いた苦味抑制方法である。 That is, the present invention is 75μm or less of the particles more than 60%, the specific surface area is bitterness suppression method using a mannitol powder is less than 0.20 m 2 / g or more 0.64 m 2 / g as tablet material .

本発明の対象となる苦味物質としては、特に制限はないが、苦味のある、医薬品成分や食品またはそれらの組み合わせなどが挙げられる。例えば医薬品成分であれば、滋養強壮保健薬、解熱鎮痛消炎薬、向精神薬、抗不安薬、抗うつ薬、催眠鎮静薬、鎮痙薬、中枢神経作用薬、脳代謝改善剤、脳循環改善剤、抗てんかん剤、交感神経興奮剤、胃腸薬、制酸剤、抗潰瘍剤、鎮咳去痰剤、鎮吐剤、呼吸促進剤、気管支拡張剤、抗アレルギー薬、歯科口腔用薬、抗ヒスタミン剤、強心剤、不整脈用剤、利尿薬、血圧降下剤、血管収縮薬、冠血管拡張薬、末梢血管拡張薬、高脂血症用剤、利胆剤、抗生物質、化学療法剤、糖尿病用剤、骨粗しょう症用剤、抗リウマチ薬、骨格筋弛緩薬、鎮けい剤、ホルモン剤、アルカロイド系麻薬、サルファ剤、痛風治療薬、血液凝固阻止剤、抗悪性腫瘍剤、アルツハイマー病治療薬などに使用されるものが挙げられる。また、食品であれば、栄養補助食品等と呼ばれる食品サプリメントや特定保健用食品、栄養機能食品等の保健機能食品、健康食品などに用いられるものが挙げられる。   Although there is no restriction | limiting in particular as a bitter substance used as the object of this invention, A pharmaceutical component, a foodstuff, those combinations, etc. with a bitter taste are mentioned. For example, in the case of pharmaceutical ingredients, nourishing tonics, antipyretic analgesics, antipsychotics, anxiolytics, antidepressants, hypnotic sedatives, antispasmodics, central nervous system agonists, brain metabolism improvers, cerebral circulation improvers Antiepileptics, sympathomimetics, gastrointestinal drugs, antacids, anti-ulcers, antitussive expectorants, antiemetics, respiratory stimulants, bronchodilators, antiallergic drugs, dental and oral drugs, antihistamines, cardiotonics, arrhythmias Agents, diuretics, antihypertensive agents, vasoconstrictors, coronary vasodilators, peripheral vasodilators, hyperlipidemia agents, diuretics, antibiotics, chemotherapeutic agents, diabetics, osteoporosis Drugs, antirheumatic drugs, skeletal muscle relaxants, antispasmodic drugs, hormone drugs, alkaloid narcotics, sulfa drugs, gout drugs, anticoagulants, antineoplastic drugs, Alzheimer's disease drugs, etc. It is done. In addition, as for foods, food supplements called nutritional supplements, foods for specified health use, health functional foods such as nutritional functional foods, health foods and the like can be mentioned.

ここで本発明における苦味とは、口腔内に苦味物質を摂取して10秒経過するまでに感じる苦味の先味、また摂取して10秒経過後から25秒経過するまでに感じる苦味の中味をいう。苦味物質を摂取する方法は、苦味物質をそのまま摂取してもよいし、苦味物質が錠剤等に包含されたものを摂取してもよい。   Here, the bitter taste in the present invention refers to the bitter taste of the bitter taste that is felt until 10 seconds have elapsed after ingesting the bitter substance in the oral cavity, and the content of the bitter taste that is felt until 25 seconds have elapsed after 10 seconds have elapsed since ingestion. Say. As a method for ingesting a bitter substance, the bitter substance may be ingested as it is, or a bitter substance contained in a tablet or the like may be ingested.

本発明におけるマンニトール粉末とは、75μm以下の粒子が60%以上であり、比表面積が0.20m/g以上0.64m/g未満のものであれば、特に制限なく使用することができ、50μm以下の粒子が80%以上のものがより好ましい。比表面積は、比表面積測定装置を用いて測定した値であり、具体的には自動比表面積測定装置(Gemini 2375:SHIMADZU社製)を用いた窒素ガス吸着によるBET法で測定する。また、粒度は、レーザー回折式粒度分布測定機を用いて測定した体積基準分布における累積値であり、具体的にはレーザー回折式粒度分布測定機(MICROTRAC MT3000:マイクロトラック・ベル社製)を用いて測定する。なお、本発明のマンニトール粉末における、比表面積と粒度を得るために、例えば、原料のマンニトール粉末を粉砕し、必要に応じて分級して調整してもよい。 The mannitol powder in the present invention, it is 75μm or less particles of 60% or more, as long as the specific surface area is less than 0.20 m 2 / g or more 0.64 m 2 / g, can be used without limitation More preferably, particles having a particle size of 50 μm or less are 80% or more. The specific surface area is a value measured using a specific surface area measuring apparatus, and specifically, is measured by a BET method by nitrogen gas adsorption using an automatic specific surface area measuring apparatus (Gemini 2375: manufactured by SHIMADZU). The particle size is a cumulative value in a volume-based distribution measured using a laser diffraction particle size distribution measuring device, and specifically, a laser diffraction particle size distribution measuring device (MICROTRAC MT3000: manufactured by Microtrack Bell) is used. To measure. In order to obtain the specific surface area and particle size in the mannitol powder of the present invention, for example, the raw material mannitol powder may be pulverized and classified as necessary.

さらに、本発明に係るマンニトール粉末は造粒し顆粒にして、錠剤用原料として使用することもできる。顆粒を調製する工程における造粒方法や造粒条件は特に制限されないが、精製水やエタノール水溶液、マンニトールやマルチトール、キシリトール、ソルビトール、エリスリトールなどの各種糖アルコール類の水溶液、ヒドロキシプロピルセルロースやメチルセルロースなどの結合剤から選択されるバインダーを用いた湿式造粒が好ましく、例えば一般的な流動層造粒機、攪拌造粒機、押し出し造粒機、転動流動層造粒機等を用いることができる。造粒後は、必要に応じて、篩別、乾燥を行うことができ、粒径の選別を行うこともできる。   Furthermore, the mannitol powder according to the present invention can be granulated and granulated to be used as a raw material for tablets. The granulation method and granulation conditions in the step of preparing the granule are not particularly limited, but purified water, ethanol aqueous solution, aqueous solutions of various sugar alcohols such as mannitol, maltitol, xylitol, sorbitol, erythritol, hydroxypropylcellulose, methylcellulose, etc. Wet granulation using a binder selected from these binders is preferred. For example, a general fluidized bed granulator, stirring granulator, extrusion granulator, rolling fluidized bed granulator or the like can be used. . After granulation, if necessary, sieving and drying can be performed, and particle size can also be selected.

次に、本発明に係る錠剤の製造方法について説明する。錠剤の製造方法には、単発式打錠機やロータリー式打錠機等の通常用いられる圧縮成形機を使用することが出来る。本発明の錠剤用原料は、適宜混合して使用され、錠剤に成形される。錠剤の形状は特に制限されず、円形錠、平錠、普通R錠、スミ角錠、スミ丸錠、糖衣錠、二段R錠を例示することができ、また錠剤に割線を入れた分割錠とすることもできる。なお、錠剤用原料には、本発明におけるマンニトール粉末をそのまま用いることも可能であるが、顆粒にして用いた方が、より使用し易いため好ましい。すなわち、顆粒として使用することで、錠剤を得る際に生じる、キャッピング現象やスティッキング現象等の打錠障害の発生を防止できる。   Next, the manufacturing method of the tablet which concerns on this invention is demonstrated. For the tablet production method, a commonly used compression molding machine such as a single-shot tableting machine or a rotary tableting machine can be used. The raw materials for tablets of the present invention are used by mixing as appropriate, and are formed into tablets. The shape of the tablet is not particularly limited, and can be exemplified by round tablets, flat tablets, ordinary R tablets, Sumi square tablets, Sumi round tablets, sugar-coated tablets, two-stage R tablets, You can also In addition, although the mannitol powder in this invention can also be used as it is for the raw material for tablets, it is preferable to use it as a granule because it is easier to use. That is, by using it as a granule, it is possible to prevent the occurrence of tableting troubles such as capping phenomenon and sticking phenomenon that occur when tablets are obtained.

また、本発明に係る錠剤用原料には、通常食品や医薬品に使用する成分であれば制限なく本発明のマンニトール粉末と併せて、包含させることができる。例えば、アスコルビン酸やクエン酸やリンゴ酸などの各種酸味料、アセスルファムKやスクラロースやアスパルテームなどの高甘味剤、マルチトールやキシリトールやソルビトールやエリスリトールなどの各種糖アルコール類、ミントやバニラ、グレープフルーツ、抹茶などの各種フレーバー類や香味料類、滑沢剤、崩壊剤、崩壊助剤、導水剤、発砲剤、着色料、その他、各種基剤や食品素材の他、医薬品類、などを包含させることが可能である。特に、各種フレーバー類や香味料類の添加は、マンニトール粉末の口どけの良さに伴う甘味の立ち上がりにより、それらの風味が阻害されることなく、むしろ向上するため好ましい。   In addition, the raw material for tablets according to the present invention can be included together with the mannitol powder of the present invention without limitation as long as it is a component that is usually used in foods and pharmaceuticals. For example, various acidulants such as ascorbic acid, citric acid and malic acid, high sweeteners such as acesulfame K, sucralose and aspartame, various sugar alcohols such as maltitol, xylitol, sorbitol and erythritol, mint, vanilla, grapefruit, matcha And other flavors and flavors, lubricants, disintegrants, disintegration aids, water-conducting agents, foaming agents, colorants, and other bases and food materials as well as pharmaceuticals Is possible. In particular, the addition of various flavors and flavors is preferable because the flavor of the mannitol powder is improved without being hindered by the rise of sweetness associated with the good mouthfeel.

本発明によると、特定の比表面積および粒度をもつマンニトール粉末を錠剤用原料として用いることによって、従来よりもさらに効果的に、苦味物質の苦味を抑制することができる。   According to the present invention, by using mannitol powder having a specific specific surface area and particle size as a raw material for tablets, the bitterness of bitter substances can be suppressed more effectively than before.

以下に本発明について実施例を挙げてさらに詳細に説明するが、本発明は以下の実施例に限定されるものではない。   Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited to the following examples.

実施例において、苦味物質であるキニーネ硫酸塩は和光純薬工業社の製品を、カフェインはカフェイン(抽出物)という白鳥製薬社の製品を、それぞれ使用した。   In the examples, quinine sulfate, which is a bitter substance, was a product of Wako Pure Chemical Industries, Ltd., and caffeine was a product of Shiratori Pharmaceutical Co., Ltd. called caffeine (extract).

また、実施例において、崩壊剤であるコリドンCL−FはBASFジャパン社の製品を、滑沢剤であるステアリン酸マグネシウムは和光純薬工業社の製品を、フレーバー類であるグレープフルーツフレーバーはドライコートグレープフルーツフレーバー#3261という高田香料社の製品を、それぞれ使用した。   In the examples, Kollidon CL-F, a disintegrating agent, is a product of BASF Japan, Magnesium stearate, a lubricant, is a product of Wako Pure Chemical Industries, and Grapefruit flavor, which is a flavor, is a dry-coated grapefruit. A product of Takada Incense Co., Ltd. called Flavor # 3261 was used.

さらに、実施例において、バインダーとして用いたヒドロキシプロピルセルロースはHPC‐SSLという日本曹達社の製品を使用した。また、マンニトール粉末はマンニットC、マンニットPおよびマンニットSという三菱商事フードテック社の製品を、それぞれ使用した。それぞれの、平均粒子径と粒度、比表面積の測定値を表1に示す。なお、平均粒子径は、レーザー回折式粒度分布測定機(MICROTRAC MT3000:マイクロトラック・ベル社製)を用いて測定した体積基準分布におけるメジアン径の値である。   Furthermore, in the examples, the hydroxypropyl cellulose used as a binder was a product of Nippon Soda Co., Ltd. called HPC-SSL. Further, as the mannitol powder, products manufactured by Mitsubishi Corporation Food Tech Co., Ltd., Mannit K, Mannit P and Mannit S were used. Table 1 shows the measured values of average particle size, particle size, and specific surface area. In addition, an average particle diameter is the value of the median diameter in the volume reference | standard distribution measured using the laser diffraction type particle size distribution analyzer (MICROTRAC MT3000: Microtrac Bell make).

Figure 2017125002
Figure 2017125002

表1に記載の各種マンニトール粉末原料を流動層造粒装置(フロイント産業社製「FLO−1」)で、バインダーとして濃度8重量%のヒドロキシプロピルセルロース溶液を噴霧しながら造粒して、種々のマンニトール顆粒を得た。造粒条件は、仕込量500g、設定温度:吸気60〜80℃、排気30〜35℃、バインダー溶液94g、噴霧速度:8g/分(連続噴霧)とした。得られたマンニトール顆粒について、表2に記載の粉体配合率表に示す混合粉体を180mg調製し、錠剤用原料とした。なお、キニーネ硫酸塩は、あらかじめ各種マンニトール顆粒に倍散して混合した。打錠では、錠剤用原料を小型高速回転式錠剤機VIRGO(菊水製作所社製)により、剤型8mm隅丸、錠剤重量180mg、杵たて数1本、回転数20rpm、打錠圧800〜1200kgfの条件で、錠剤硬度が5kgfになるように、直接打錠法による打錠を行い、錠剤を成形した。さらに、得られた錠剤について官能評価を行った。   Various mannitol powder materials listed in Table 1 were granulated with a fluidized bed granulator ("FLO-1" manufactured by Freund Sangyo Co., Ltd.) while spraying a hydroxypropyl cellulose solution having a concentration of 8% by weight as a binder. Mannitol granules were obtained. The granulation conditions were as follows: charged amount 500 g, set temperature: intake air 60 to 80 ° C., exhaust gas 30 to 35 ° C., binder solution 94 g, spray rate: 8 g / min (continuous spray). About the obtained mannitol granules, 180 mg of the mixed powder shown in the powder blending ratio table shown in Table 2 was prepared and used as a raw material for tablets. The quinine sulfate was mixed in advance with various mannitol granules. In tableting, the raw material for tablets is prepared by a small high-speed rotary tablet machine VIRGO (manufactured by Kikusui Seisakusho Co., Ltd.). Under these conditions, tableting was performed by the direct tableting method so that the tablet hardness was 5 kgf, and tablets were formed. Furthermore, sensory evaluation was performed about the obtained tablet.

Figure 2017125002
Figure 2017125002

官能評価では、マンニットS錠剤を基準品にして、各種マンニトール錠剤の評価を行った。評価は、マンニトール錠剤ごとに8名のパネルを用いて行った。   In the sensory evaluation, various mannitol tablets were evaluated using the Mannit S tablet as a reference product. Evaluation was performed using a panel of 8 persons for each mannitol tablet.

錠剤の官能評価は、以下のように行った。   The sensory evaluation of the tablets was performed as follows.

サンプルの「苦さ」について、基準品に対して非常に強い(−3点)〜基準品と同じ(0点)〜非常に弱い(+3点)の7段階の点数で評価し、平均値を求めた。また、サンプルの「グレープフルーツ風味」について、基準品に対して非常に悪い(−3点)〜基準品と同じ(0点)〜非常に良い(+3点)の7段階の点数で評価し、平均値を求めた。結果を表3に示す。   The “bitterness” of the sample was evaluated with a score of 7 levels from very strong (−3 points) to the standard product to the same (0 points) to very weak (+3 points) as the standard product. Asked. In addition, the “grapefruit flavor” of the sample was evaluated based on a 7-point score that was very bad (−3 points) to the same as the reference product (0 points) to very good (+3 points). The value was determined. The results are shown in Table 3.

Figure 2017125002
Figure 2017125002

官能評価結果より、マンニットC錠剤およびマンニットP錠剤のいずれの錠剤においても、基準品に比べ、苦さが弱いという評価になることが確認された。   From the sensory evaluation results, it was confirmed that both the Mannit C tablet and the Mannit P tablet were evaluated to be less bitter than the reference product.

実施例1で得られたマンニトール顆粒について、表4に記載の粉体配合率表に示す混合粉体を180mg調製し、錠剤用原料とした。打錠は、実施例1と同様に行った。さらに、得られた錠剤について官能評価を行った。   About the mannitol granule obtained in Example 1, 180 mg of the mixed powder shown in the powder blending ratio table shown in Table 4 was prepared and used as a raw material for tablets. Tableting was performed in the same manner as in Example 1. Furthermore, sensory evaluation was performed about the obtained tablet.

Figure 2017125002
Figure 2017125002

官能評価では、カフェイン0.001gとマンニットS錠剤とを同時摂取したものを基準にして、カフェイン0.001gと各種マンニトール錠剤とを同時摂取したものの評価を行った。評価は、マンニトール錠剤ごとに8名のパネルを用いて行った。   In the sensory evaluation, an evaluation was made on what was simultaneously ingested 0.001 g of caffeine and various mannitol tablets, based on what was simultaneously ingested 0.001 g of caffeine and Mannitol S tablets. Evaluation was performed using a panel of 8 persons for each mannitol tablet.

錠剤の官能評価は、以下のように行った。   The sensory evaluation of the tablets was performed as follows.

サンプルの「苦さ」について、基準に対して非常に強い(−3点)〜基準と同じ(0点)〜非常に弱い(+3点)の7段階の点数で評価し、平均値を求めた。結果を表5に示す。   About the "bitterness" of the sample, it was evaluated by 7-point score from very strong (-3 points) to the standard (same as 0 points) to very weak (+3 points), and an average value was obtained. . The results are shown in Table 5.

Figure 2017125002
Figure 2017125002

官能評価結果より、マンニットC錠剤およびマンニットP錠剤のいずれの錠剤においても、基準に比べ、苦さが弱いという評価になることが確認された。   From the sensory evaluation results, it was confirmed that both the Mannit C tablet and the Mannit P tablet were evaluated to be less bitter than the standard.

以上より、本発明に係る方法により、従来よりもさらに効果的に、苦味物質の苦味を抑制することが可能となった。   As described above, the method according to the present invention can more effectively suppress the bitterness of the bitter substance than before.

Claims (1)

75μm以下の粒子が60%以上であり、比表面積が0.20m/g以上0.64m/g未満であるマンニトール粉末を錠剤用原料として用いた苦味抑制方法。 And a 75μm or less particles of 60% or more, bitterness suppression method using a mannitol powder specific surface area is less than 0.20 m 2 / g or more 0.64 m 2 / g as tablet material.
JP2016077765A 2016-01-13 2016-04-08 Bitter taste suppressing method using mannitol powders Pending JP2017125002A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016004005 2016-01-13
JP2016004005 2016-01-13

Publications (1)

Publication Number Publication Date
JP2017125002A true JP2017125002A (en) 2017-07-20

Family

ID=59364549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016015131A Pending JP2017125001A (en) 2016-01-13 2016-01-29 Bitter taste suppressing method using mannitol powders
JP2016077765A Pending JP2017125002A (en) 2016-01-13 2016-04-08 Bitter taste suppressing method using mannitol powders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016015131A Pending JP2017125001A (en) 2016-01-13 2016-01-29 Bitter taste suppressing method using mannitol powders

Country Status (1)

Country Link
JP (2) JP2017125001A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113423277A (en) * 2019-02-20 2021-09-21 三得利控股株式会社 Granular composition containing milk-derived protein, method for producing same, and method for improving dispersibility of granular composition containing milk-derived protein

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021300A1 (en) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 Novel excipient for mannitol tableting
JP2010070466A (en) * 2008-09-16 2010-04-02 Kyoto Pharmaceutical Industries Ltd Disintegrating tablet in oral cavity
JP2013127009A (en) * 2006-08-08 2013-06-27 Kissei Pharmaceutical Co Ltd Oral disintegrating tablet having masked bitter taste and method for producing the same
JP2015098467A (en) * 2013-10-15 2015-05-28 Meiji Seikaファルマ株式会社 Formulation with improved stability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013127009A (en) * 2006-08-08 2013-06-27 Kissei Pharmaceutical Co Ltd Oral disintegrating tablet having masked bitter taste and method for producing the same
WO2010021300A1 (en) * 2008-08-18 2010-02-25 三菱商事フードテック株式会社 Novel excipient for mannitol tableting
JP2010070466A (en) * 2008-09-16 2010-04-02 Kyoto Pharmaceutical Industries Ltd Disintegrating tablet in oral cavity
JP2015098467A (en) * 2013-10-15 2015-05-28 Meiji Seikaファルマ株式会社 Formulation with improved stability

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PHARM TACH JAPAN, vol. Vol.29(4), JPN6019040279, 2013, pages 87 - 91, ISSN: 0004220263 *
PHARM THEC JAPAN, vol. Vol.31(4), JPN6019040277, 2015, pages 95 - 98, ISSN: 0004220262 *
日本薬剤学会 第28年会 〜薬剤学、健康への貢献〜 プログラム・抄録集, JPN6019040282, 26 April 2013 (2013-04-26), pages 310, ISSN: 0004220265 *
第30回 製剤と粒子設計 シンポジウム講演要旨集, JPN6019040280, 10 October 2013 (2013-10-10), pages 118 - 119, ISSN: 0004220264 *

Also Published As

Publication number Publication date
JP2017125001A (en) 2017-07-20

Similar Documents

Publication Publication Date Title
JP5537943B2 (en) Fast disintegrating solid preparation
WO2000078292A1 (en) Quickly disintegrating solid preparations
JP5074190B2 (en) Orally rapidly disintegrating tablets
JP2001058944A (en) Rapidly disintegrating solid formulation
JPH0948726A (en) Rapidly disintegrating preparation in mouth cavity and its production
JP5342028B2 (en) Orally disintegrating tablets
KR20110018424A (en) Tablet quickly disintegrating in the oral cavity and method for producing the same
KR20080039410A (en) Orally disintegratable tablet
JP3996626B2 (en) Orally disintegrating tablets
KR102018385B1 (en) Orally disintegrating tablet and process for production thereof
JP2006070046A (en) Quick disintegrable solid preparation
JP5945191B2 (en) Intraoral quick disintegrating tablet
JP2003034655A (en) Fast degradable solid tablet
JP5337430B2 (en) Orally disintegrating tablets
JP6482552B2 (en) Oral film dosage form that is immediately wettable without surfactants and polyhydric alcohols
JP2009179604A (en) Quickly disintegrating tablet in oral cavity
JP5204976B2 (en) Fast disintegrating tablets containing iguratimod
JP4131747B2 (en) Manistol-containing cilostazol orally disintegrating powder
JP2010241760A (en) Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same
JP6092672B2 (en) Orally rapidly disintegrating tablets
JP2019014666A (en) Orally disintegrating tablet, and method for producing the same
JP2017125002A (en) Bitter taste suppressing method using mannitol powders
WO2022102457A1 (en) Linagliptin-containing orally disintegrating tablet
JPH08143473A (en) Easily administrable seeded tablet preparation
JP2014227366A (en) Compression-molding formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160415

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190328

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201028